New drug combo aims to halt endometrial cancer growth
NCT ID NCT03008408
First seen Nov 21, 2025 · Last updated Apr 28, 2026 · Updated 21 times
Summary
This study tests whether adding ribociclib to the standard combination of everolimus and letrozole can better control advanced or recurrent endometrial cancer. About 90 participants will receive either the two-drug or three-drug regimen. The goal is to see if the triple therapy improves the rate of tumor shrinkage or stabilization.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lyndon Baines Johnson General Hospital
Houston, Texas, 77026-1967, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.